N/A
Completed N=50
Treatment of Nasal Airway Obstruction Using the Aerin Medical Device
Source: ClinicalTrials.gov NCT02914236 ↗Enrolled (actual)
50
Serious AEs
4.0%
Results posted
Mar 2018
Primary outcomePrimary: Improvement in NOSE Score — 54.8 units on a scale — p=<0.0001
Summary
Evaluation of the Aerin Medical Device used for the treatment of nasal obstruction.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Improvement in NOSE Score |
54.8 | <0.0001 sig |
| SECONDARY NOSE Responder Rate |
93.9 | <0.0001 sig |
| SECONDARY Percentage of Participants With Treatment-Related Adverse Events (Safety) |
20 | — |
Eligibility Criteria
Inclusion Criteria
- Seeking treatment for nasal obstruction and willing to undergo an office-based procedure
- Nasal Obstruction Symptom Evaluation (NOSE) score of ≥ 60 at Baseline
- Nasal valve is a primary or significant contributor to the subject's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the subject has a positive response to any of the following temporary measures (based on patient history or office exam):
- Use of external nasal dilator strips (e.g., Breathe Right Strips)
- Q-Tip test (manual intranasal lateralization)
- Use of nasal stents
- Cottle Maneuver (manual lateral retraction of the cheek)
Exclusion Criteria
- Prior surgical treatment of the nasal valve
- Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past twelve (12) months
- Chronic sinusitis, recurrent sinusitis, or allergies leading to nasal obstruction
- Septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be a significant contributor to the subject's nasal obstruction symptoms
- Known or suspected allergies or contraindications for any general or local anesthetic agents and / or any antibiotic medications
- Known or suspected to be pregnant, or is lactating
- Other medical conditions which in the opinion of the investigator could predispose the subject to poor wound healing or increased surgical risk
Data sourced from ClinicalTrials.gov (NCT02914236). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.